Results 101 to 110 of about 21,301 (157)

Cytotoxic activity of selinexor in BRAF^V600E-driven pediatric low-grade glioma 3D cultures. [PDF]

Acta Neuropathol Commun
Zeiser C, Emperador M, Herter S, Sigaud L, Stroh-Dege A, Loboda A, Kolodziejczak A, Zeuner S, Digel LJ, Frese K, Chilian B, Freitas M, Kelm JM, Ǿra I, Vogl D, Schuhmann MU, Peterziel H, Sigaud R, Selt F, Milde T, Witt O, Oehme I.   +21 more
europepmc   +1 more source

Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report. [PDF]

Case Rep Pediatr
Brown G, McNab S, Keogh S, Massie J, Eastaugh L, Pathmanathan L, Bertinetti M, Sullivan M, Orme L, Cloney T, Brown NJ, Tan TY, Quin R, Pertile M, Moon A, Bekhit E, Penington T.   +16 more
europepmc   +1 more source

Acyclic Retinoid Attenuates STAT3 Signaling and Reduces In Vitro Growth of A375-Derived Dabrafenib Plus Trametinib-Resistant Melanoma Cells. [PDF]

Int J Mol Sci
Nishizawa M, Kimura M, Hamada H, Yajima I.   +3 more
europepmc   +1 more source

Macrophages as Drivers of Resistance to Dabrafenib Plus Trametinib Therapy in Anaplastic Thyroid Cancer. [PDF]

Int J Mol Sci
Rodrigues R, Garcia B, Rito M, Roque R, Pereira T, Morgado S, Tavares V, da Silva TN, Leite V, Cavaco BM.   +9 more
europepmc   +1 more source

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600-Mutant Advanced Melanoma. [PDF]

J Clin Oncol
Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara M, Arance A, Gaudy-Marqueste C, Stroyakovskiy D, Lebbe C, Maio M, Del Vecchio M, Boghikian PS, Gutzmer R, Depenni R, Miskic M, Russo M, Dummer R.   +24 more
europepmc   +1 more source

The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors. [PDF]

Clin Cancer Res
Jänne PA, Johnson ML, Li J, Pant S, Dünzinger U, Ilia L, Möldner K, Soh JE, Yamamoto N.   +8 more
europepmc   +1 more source

Dabrafenib and trametinib-induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma. [PDF]

JCEM Case Rep
Nagano K, Suzuki M, Morikawa S, Watanabe R, Ohara T, Hara K.   +5 more
europepmc   +1 more source

Effects of MEK-inhibitor treatment in infants with lymphatic abnormalities in noonan syndrome. [PDF]

Front Pediatr
Wagenpfeil J, Hoß K, Henkel A, Kütting DL, Luetkens JA, Mueller A, Pieper CC, Groteklaes A.   +7 more
europepmc   +1 more source

Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer. [PDF]

Curr Issues Mol Biol
Saruhan S, Özdemir D, Ağca CA.
europepmc   +1 more source

TEAD inhibitors re-sensitize drug-resistant NF1 MPNST cells to MEK inhibitors. [PDF]

MicroPubl Biol
Yang Y, Guo J, Gurunathan S, Schechter S, Field J.   +4 more
europepmc   +1 more source